News
AMPH
29.26
+2.20%
0.63
Is Amphastar (AMPH) Turning Margin Compression Into a Test of Its Operational Discipline?
Simply Wall St · 3d ago
Weekly Report: what happened at AMPH last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at AMPH last week (0119-0123)?
Weekly Report · 01/26 10:01
Amphastar Pharmaceuticals (AMPH) Gets a Hold from Bank of America Securities
TipRanks · 01/20 11:56
Weekly Report: what happened at AMPH last week (0112-0116)?
Weekly Report · 01/19 10:05
A Look At Amphastar Pharmaceuticals (AMPH) Valuation After The AMP-110 License Agreement With Nanjing Hanxin
Simply Wall St · 01/15 16:20
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving
Barchart · 01/15 15:04
Trump admin rolls back $2B in mental health, addiction grant cuts—report
Seeking Alpha · 01/15 11:49
Amphastar Licenses ACTH Analog AMP-110 for North America
TipRanks · 01/12 22:53
Amphastar Pharmaceuticals Signs Deal With Chinese Co. For Global Drug Development
Dow Jones · 01/12 22:52
Amphastar Pharmaceuticals Showcases Pipeline Shift to Proprietary and Biosimilar Products in New Presentation
Reuters · 01/12 21:35
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
Barchart · 01/12 16:24
Amphastar Licenses New Synthetic ACTH Drug for Inflammatory Diseases in US and Canada
Benzinga · 01/12 11:21
AMPHASTAR PHARMACEUTICALS: ADDITIONAL PAYMENTS TO HANXIN OF UP TO $14 MLN IN DEVELOPMENT MILESTONE PAYMENTS, UP TO $75 MLN IN SALES MILESTONE PAYMENTS
Reuters · 01/12 11:03
AMPHASTAR PHARMACEUTICALS: LICENSE AGREEMENT WITH NANJING HANXIN PHARMACEUTICAL TECHNOLOGY FOR FULLY SYNTHETIC CORTICOTROPIN COMPOUND
Reuters · 01/12 11:03
Amphastar Pharmaceuticals Signs Exclusive License Agreement for Synthetic ACTH Compound
Reuters · 01/12 11:00
Weekly Report: what happened at AMPH last week (0105-0109)?
Weekly Report · 01/12 10:05
Is New BofA Coverage And J.P. Morgan Spotlight Altering The Investment Case For Amphastar (AMPH)?
Simply Wall St · 01/10 16:21
Is Amphastar Pharmaceuticals (AMPH) Attractively Priced After Recent Share Price Weakness?
Simply Wall St · 01/09 10:22
3 Low-Volatility Stocks We Find Risky
Barchart · 01/08 04:56
More
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.